ALTA-002 / ALX Oncology, Tallac Therap - LARVOL DELTA

OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights (Businesswire) - "ALTA-002: Tallac Therapeutics disclosed U.S. Food and Drug Administration clearance of its investigational new drug application for ALTA-002, a SIRPα targeting toll-like receptor agonist antibody conjugates (TRAAC), in patients with advanced solid tumors."

IND • Solid Tumor

Patterns of tooth agenesis in individuals with Down syndrome: A secondary analysis using the Tooth Agenesis Code. (PubMed, Spec Care Dentist) - "Predominant TA patterns exist in DS. Observation of mandibular central incisor agenesis can promote early diagnosis of oligodontia in DS."

Journal • Developmental Disorders • Genetic Disorders

ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones (GlobeNewswire) - "Filing an IND for ALTA-002, a SIRPα Toll-like receptor agonist antibody conjugate in collaboration with Tallac Therapeutics in the first half of 2023."

IND • Oncology • Solid Tumor

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023 (GlobeNewswire) - "Anticipated Milestones in 2023...Filing an IND for ALTA-002, a SIRPα Toll-like receptor agonist antibody conjugate ('TRAAC') in collaboration with Tallac Therapeutics in the first half of 2023; Expansion of the ADC platform acquired from ScalmiBio to identify clinical development candidates by the second half of 2023."

IND • Oncology • Solid Tumor

OSE Immunotherapeutics Announces Corporate Update and H1 2022 Results (Businesswire) - "A newly formed SAB combining the expertise of renowned scientific and international key-opinion leaders in the fields of immunology, immuno-oncology, inflammation and immunotherapy...The SAB includes...Dr. Jennifer Wargo...."

Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors (Businesswire) - "Tallac Therapeutics, Inc...announced that the first patient has been dosed with TAC-001 in a Phase 1/2 clinical trial for patients with advanced or metastatic solid tumors. TAC-001 is the company’s lead clinical candidate from its novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform and the first to enter the clinic...'As this study advances, we are also progressing additional assets in our pipeline and plan to file an investigational new drug application (IND) in the beginning of next year for our Phase 1 study in partnership with ALX Oncology Holdings Inc...for ALTA-002.'....The Phase 1/2 trial, known as INCLINE-101 (NCT05399654), is an open label, multicenter, dose escalation and expansion study of TAC-001 in patients with select advanced or metastatic solid tumors. "

IND • New P1 trial • Trial status • Oncology • Solid Tumor

ALTA-002, a SIRPα-directed TLR9 agonist antibody conjugate activates myeloid cells and promotes anti-tumor immunity (SITC 2021) - "Conclusions These results demonstrate the unique properties of systemically administered ALTA-002, which integrates TLR9 activation and blockade of CD47-SIRPα interaction on myeloid cells to engender both innate and adaptive anti-tumor immune responses. These data support the development of ALTA-002 as an anti-cancer therapeutic for a variety of tumor malignancies."

IO biomarker • Genito-urinary Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • SIRPA

ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights (GlobeNewswire) - "...'we expect a data-filled fourth quarter, which will include four poster presentations at the upcoming SITC conference, including...the trial designs from both our Phase 2 head and neck cancer studies in collaboration with Merck (ASPEN-03 and ASPEN-04) and preclinical data for ALTA-002, a first in class SIRPa-directed TLR9 agonist antibody conjugate being developed in collaboration with Tallac Therapeutics....Later this quarter, we expect to report additional Phase 1b data from ASPEN-02 in myelodysplastic syndromes, and the initiation of ASPEN-06, our randomized Phase 2 trial in second line gastric cancer'..."

Clinical protocol • P1 data • Preclinical • Trial initiation date • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hematological Malignancies • Myelodysplastic Syndrome • Oncology

ALX Oncology Announces Four Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting (GlobeNewswire) - "ALX Oncology Holdings Inc...announced that four abstracts have been accepted for presentation at the SITC 36th Annual Meeting in Washington D.C. from November 10 –14, 2021. The abstracts, which will be presented in a poster session, include new clinical data from ASPEN-01, the ongoing Phase 1b study of evorpacept (also known as ALX148) in patients with head and neck squamous cell carcinoma and with gastric/gastroesophageal cancer, and clinical trial in progress presentations on ASPEN-03 and ASPEN-04, our Phase 2 head and neck cancer studies in collaboration with Merck. In addition, preclinical data will be presented on ALTA-002, a first-in-class SIRPα-directed TLR9 agonist antibody conjugate, which is being developed in collaboration with Tallac Therapeutics."

Clinical data • Preclinical • Esophageal Cancer • Gastric Cancer • GastroEsophageal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Oncology • Squamous Cell Carcinoma of Head and Neck

ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics (GlobeNewswire) - “ALX Oncology…and Tallac Therapeutics…announced a collaboration to jointly develop, manufacture, and commercialize a novel class of cancer immunotherapeutics. Under the terms of the agreement, ALX Oncology and Tallac will share equally in the cost of research and development and any profits or losses incurred…'The goal of our collaboration with ALX Oncology is to advance SIRPα TRAAC, a systemically delivered TLR9 agonist targeting dendritic cells via SIRPα receptors, enabling a powerful innate and adaptive anti-tumor immune response'....'Collaborating with Tallac and their novel TRAAC platform broadens ALX Oncology’s therapeutic strategies to activate the innate immune system and SIRPα TRAAC complements our lead product candidate, ALX148..."

Licensing / partnership • Oncology